Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks
罗氟司特泡沫剂0.3%治疗脂溢性皮炎患者的长期安全性和有效性：一项长达52周的II期开放标签试验
期刊:American Journal of Clinical Dermatology
影响因子:8.8
doi:10.1007/s40257-025-00984-2
Alexis, Andrew F; Bukhalo, Michael; Cook-Bolden, Fran E; Del Rosso, James Q; Draelos, Zoe D; DuBois, Janet C; Ferris, Laura K; Forman, Seth B; Kempers, Steven E; Kircik, Leon H; Lain, Edward; Moore, Angela Y; Pariser, David M; Raoof, Joseph; Zirwas, Matthew J; Seal, Melissa S; Kato, Saori; Chu, David H; Krupa, David; Snyder, Scott; Burnett, Patrick; Berk, David R
